Osteopore Ltd Delivers First Custom Orthopaedic Device to Hainan Hospital
First custom orthopaedic device delivered to Hainan hospital
Osteopore (ASX: OSX) has successfully delivered its first custom orthopaedic device for its first patient at the Hainan branch hospital of Shanghai Ruijin Hospital. The milestone was disclosed to the ASX on 14 July 2026.
The hospital sits within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
Surgery for the first patient was originally scheduled for June 2026. This has now been rescheduled for July 2026, according to the company.
Osteopore is an Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The delivery represents the first tangible step in translating the company’s recent Hainan regulatory approval into clinical and commercial activity.
When big ASX news breaks, our subscribers know first
Why the Hainan FDA approval matters
As announced on 26 May 2026, Osteopore received approval from the Hainan Medical Products Administration (Hainan FDA) for the clinical use and sale of its orthopaedic custom medical devices at the Hainan branch hospital of Shanghai Ruijin Hospital.
The Hainan FDA approval, announced on 26 May 2026, positioned Shanghai Ruijin Hospital as the clinical anchor for Osteopore’s China entry, with the 3A-ranked institution ranked #32 globally by the Nature Index and serving as a national-level platform for clinical innovation adoption.
The Hainan FDA approval is a license which enables the Company to sell and market its devices in the Boao Lecheng International Medical Tourism Pilot Zone. Access beyond this zone is a future pathway rather than a current right.
According to the company, the Hainan FDA approval pathway allows companies to generate real-world data that can later support nationwide National Medical Products Administration (NMPA) registration, significantly shortening the overall time to national approval.
The company describes the approval as serving as:
-
An accelerated commercial launchpad within the Boao Lecheng Pilot Zone
-
Real-world data generation to support future NMPA registration
-
A regulatory springboard toward full China-wide market access
For investors, the delivery of the first device converts a regulatory approval into an actual clinical and commercial event, marking the first operational milestone in the company’s China market entry strategy.
How Osteopore’s 3D-printed bioresorbable technology works
Osteopore’s patented technology fabricates micro-structured scaffolds for bone regeneration using 3D printing and bioresorbable material. In plain terms, these scaffolds provide a temporary framework that supports the body’s natural bone healing process.
What distinguishes the approach is the bioresorbable polymer. The material naturally dissolves over time, leaving only natural and healthy bone tissue behind. According to the company, this significantly reduces the post-surgery complications commonly associated with permanent bone implants.
The manufacturing technique is patent-protected and unique to Osteopore. A differentiated, proprietary technology base underpins the commercial value of market access milestones such as the Hainan approval.
The bioresorbable scaffold approach that underpins the Hainan device is also being tested in a jawbone reconstruction clinical trial at Princess Alexandra Hospital in Australia, a feasibility study targeting at least 10 patients by 2028 that is building the clinical evidence base across a second anatomical application.
| Feature | What It Means | Why It Matters |
|---|---|---|
| 3D-printed scaffolds | Custom micro-structured design | Tailored to individual patients |
| Bioresorbable polymer | Dissolves naturally over time | Only healthy bone tissue remains |
| Proprietary manufacturing | Patent-protected and unique to Osteopore | Technology is unique to the company |
The next major ASX story will hit our subscribers first
What comes next for Osteopore in China
With the first device delivered and surgery scheduled for July 2026, the near-term focus turns to clinical engagement within the Boao Lecheng zone.
Over the longer arc, the company aims to build the real-world data foundation needed to support nationwide NMPA registration. No specific timelines for national approval have been disclosed.
For more information, the company has nominated Dr Yujing Lim, Chief Executive Officer, and Mark Leong, Executive Chairman, as contacts.
This delivery marks the first operational step in executing Osteopore’s China market entry strategy.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts today.